These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25731133)

  • 1. Ezetimibe plus moderate-dose simvastatin after acute coronary syndrome: what are we IMPROVEing on?
    DiNicolantonio JJ; Chatterjee S; Lavie CJ; Bangalore S; O'Keefe JH
    Am J Med; 2015 Aug; 128(8):914.e1-4. PubMed ID: 25731133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
    Cannon CP; Giugliano RP; Blazing MA; Harrington RA; Peterson JL; Sisk CM; Strony J; Musliner TA; McCabe CH; Veltri E; Braunwald E; Califf RM;
    Am Heart J; 2008 Nov; 156(5):826-32. PubMed ID: 19061694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria.
    Virani SS; Akeroyd JM; Nambi V; Maddox TM; Gillette MA; Michael Ho P; Rumsfeld J; Petersen LA; Ballantyne CM
    Am J Med; 2015 Nov; 128(11):1253-6. PubMed ID: 26071828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.
    Toth PP; Ballantyne CM; Davidson MH; Tomassini JE; Ramey DR; Neff D; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2012; 6(2):180-91. PubMed ID: 22385552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.
    Califf RM; Lokhnygina Y; Cannon CP; Stepanavage ME; McCabe CH; Musliner TA; Pasternak RC; Blazing MA; Giugliano RP; Harrington RA; Braunwald E
    Am Heart J; 2010 May; 159(5):705-9. PubMed ID: 20435175
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
    Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Reist C; McCagg A; Braunwald E; Califf RM
    Am Heart J; 2014 Aug; 168(2):205-12.e1. PubMed ID: 25066560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ezetimibe and recent clinical trials: a look on the bright side.
    Ahmed MH
    Expert Opin Drug Saf; 2010 Jul; 9(4):511-4. PubMed ID: 20377476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
    Kato ET; Cannon CP; Blazing MA; Bohula E; Guneri S; White JA; Murphy SA; Park JG; Braunwald E; Giugliano RP
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29151034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ezetimibe plus simvastatin cardiovascular outcomes study program.
    Padial LR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):17-25. PubMed ID: 18095904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
    Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
    Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study.
    Pauriah M; Elder DH; Ogston S; Noman AY; Majeed A; Wyatt JC; Choy AM; Macdonald TM; Struthers AD; Lang CC
    Heart; 2014 Jun; 100(11):867-72. PubMed ID: 24553389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events.
    Undas A; Machnik A; Potaczek DP; Wypasek E; Zmudka K; Tracz W
    J Cardiovasc Pharmacol; 2011 Aug; 58(2):167-72. PubMed ID: 21558878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carotid intima-media thickness (cIMT): a useful clinic tool or research luxury? Another view of the ENHANCE trial.
    Toutouzas P; Richter D
    Angiology; 2008; 59(2 Suppl):77S-9S. PubMed ID: 18628278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of ezetimibe/simvastatin versus simvastatin monotherapy on platelet and inflammatory biomarkers in patients with metabolic syndrome.
    Miller M; DiNicolantonio JJ; Can M; Grice R; Damoulakis A; Serebruany VL
    Cardiology; 2013; 125(2):74-7. PubMed ID: 23652826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects?
    Pesaro AE; Granger CB; Lopes RD
    Am Heart J; 2016 Feb; 172():42-4. PubMed ID: 26856214
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
    Pokharel Y; Chinnakondepalli K; Vilain K; Wang K; Mark DB; Davies G; Blazing MA; Giugliano RP; Braunwald E; Cannon CP; Cohen DJ; Magnuson EA
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
    Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
    Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.